Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy - Test2 - elhamkhani - TriplyDB

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

http://www.wikidata.org/entity/Q24632296

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment Differentiating mTOR inhibitors in renal cell carcinoma Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells mTOR-dependent cell survival mechanisms mTOR kinase inhibitors as potential cancer therapeutic drugs Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Target therapy in metastatic pheochromocytoma: current perspectives and controversies PIM1 kinase as a target for cancer therapy InTERTesting association between telomerase, mTOR and phytochemicals The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1 Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.TORC2-a new player in genome stability Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes.Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development.Pharmacologic Means of Extending Lifespan.PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.Role of Notch and its oncogenic signaling crosstalk in breast cancer.Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways.Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling.Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.mTOR kinase: a possible pharmacological target in the management of chronic pain.Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.Stratification of clear cell renal cell carcinoma by signaling pathway analysis.Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.

P2860

Q21133610-63B5956D-F5F0-4918-A188-EE3D70C9915D Q26852398-762143FC-8535-4DA1-905F-9A0219A2D5CF Q26860172-B966F860-79FF-42EE-8CA8-C6106D179EE4 Q26861403-A53083B5-8741-4EBC-A344-CBB8524EAE82 Q26864688-A680F9A7-4E8C-44D0-AC54-6CF9F5BD89E9 Q27027963-562E5BD3-0FBD-4E6C-9F47-8751E250E96C Q28071388-9B1E7E26-C68F-4D66-8B5B-8B3B49B7115A Q28087343-2AD17642-AFA4-4D64-A902-331C362AADEE Q28261162-CBBB977B-760D-4C8D-A647-D99E0B1BA688 Q28262993-A24C8068-03E0-4BF3-9B07-B267D8A11EA4 Q28276378-68F7DB20-3DF3-46A7-BD5B-80BD900FB68E Q28383826-F9FFCBB5-1513-4BCE-8103-0A65573BB104 Q28485220-32110E91-E2E3-4FDB-A7A9-99CFD156724D Q29614493-C802FE2F-0C52-4446-BAB8-66EB20008187 Q33414827-6B314580-0B69-4FB2-B6CF-854D8382FA8E Q33615797-F5E0F20E-FA17-4535-912E-1B6CB84CF6E8 Q33758255-A4A225C8-D4AF-45D9-9E51-2148ADB81EEF Q33779591-39E87856-1D09-41BA-889D-76066793ACDF Q34092436-68EDDF5C-D1EB-4B10-B4A4-00F9A588A606 Q34131149-3772D9D1-0D6D-44D8-A429-CADCDBF1C57A Q34260622-BE4C1076-A400-45A3-B0F3-E62AFDF0D419 Q34264817-87479796-C08D-4E39-9CD8-3E408811E98C Q34354609-D8293532-BA64-4066-9DA5-88E5AD472153 Q34365539-B52A47A0-2B9A-4978-9B91-D8CD9DABCC4D Q34449372-1962AAC6-DA6B-4C57-B731-9C2CA7F32E98 Q34465116-D53CFBA6-385D-4FD4-A1E2-775A4D57A9D9 Q34483665-989EBD8F-5F12-45B4-9839-79CE0F51A275 Q34525572-F856E59E-2DA2-43B7-B7A8-957C5DCF1780 Q34697373-C9FBCC36-9FB4-4BC8-A089-D75ABA721C65 Q34707066-3B2153CA-46B1-420B-930A-EC48B4EE4521 Q34762309-A2AC97AD-C035-4087-AE5B-7C17C5F7A15C Q34913885-01BD41BE-08BC-4683-9939-4E4A19BB2F88 Q34936880-05D5B3D5-3DDB-4346-9974-48B14E05B058 Q35000084-D8F7CC4D-F390-453F-9D72-0E4DDBD10CBB Q35005636-75E92F24-754F-4223-BBE3-231FF10849F9 Q35035474-19A01EDE-2BDB-45E8-B174-80BE2CD26C6C Q35048118-7E3C71F5-F9DB-4359-94D3-977E64EED479 Q35050505-A4ADFB9F-C92F-48C2-B717-8484DE461C6C Q35103884-3B5F26F5-5483-4185-8A3C-AE048239AF31 Q35165191-A53ADBDE-C663-4C8A-9DC0-AA4EADA384EC

P2860

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

http://www.wikidata.org/entity/Q24632296

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@ast

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@en

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@nl

type

label

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@ast

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@en

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@nl

prefLabel

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@ast

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@en

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@nl

P1433

Q24632296-C885605B-45DD-4FFD-BA54-65C0C9F5A107

P1476

Q24632296-3FD3FEBE-3E00-4568-8068-442BB4091B3F

P2093

Q24632296-08467EBA-8CD4-41E3-874A-20D4BC94C430

Q24632296-B9CDCC87-021A-4C43-8171-AEBED7D12D6B

P2860

Q24632296-00D51E2E-1413-479B-B147-4EBDC3FAFFD2

Q24632296-02323674-6784-4842-A0B1-9BDE240B1E0B

Q24632296-05B3A05A-D9EA-4757-9B32-6FA7025D71E6

Q24632296-07B4DCED-6249-402C-B7D2-813D48CDBFC8

Q24632296-094BF4D8-1F1C-4270-A9D3-C080DDA82C48

Q24632296-0D6D79D8-3D5C-4C78-97B9-E64F9EB8AB55

Q24632296-10D4DE8B-4B28-4870-BF8B-FF2F3ADDE508

Q24632296-17279A48-ADC1-42C1-A4DF-8469939FA1D6

Q24632296-175D05D4-7A05-406C-AC05-E6FEFFA0DC1B

Q24632296-176BFDBB-8DE0-43C5-A4DA-CE3C2F395C59

P2888

Q24632296-22A53ADA-4A31-4FB7-BB0E-A595E2DA4181

P304

Q24632296-6240F17B-AADF-46AF-A873-A2832F2D8EB3

P31

Q24632296-E11C4FDC-2480-4C85-8090-FE0EC1FA719E

P3181

Q24632296-B65D4B54-AA06-446C-8DAA-163D1199AA22

P356

Q24632296-2FE8A04E-3733-48AA-A8A3-65C5F030B357

P407

Q24632296-E34A8B2E-46E0-426D-A14E-03C8FC772FFE

P433

Q24632296-AAC748F5-5EFC-445F-B648-1807D05A3677

P478

Q24632296-89D5463F-11E6-4DDD-A9F9-9784AE7E3155

P577

Q24632296-268F4DA6-2844-452B-99AE-CC276C29B557

P5875

Q24632296-1FC6CF9A-6BA2-4D3A-A1F4-A7A009CB937F

P6179

Q24632296-664613DF-0E04-48EF-B674-F2535F620522

P698

Q24632296-84FBF5F9-7749-4330-82DE-45F09E8AB16C

P932

Q24632296-D80BF025-C1AC-450A-BBC1-08EB712DEAED

P3181

P356

P1433

P1476

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

@en

P2093

C A Sparks

http://www.w3.org/2001/XMLSchema#string

D A Guertin

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Mechanism of activation of protein kinase B by insulin and IGF-1

P2888

P304

3733-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

840856

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/ONC.2010.139

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43343256

http://www.w3.org/2001/XMLSchema#string

P6179

1051644324

http://www.w3.org/2001/XMLSchema#string

P698

20418915

http://www.w3.org/2001/XMLSchema#string

P932

3031870

http://www.w3.org/2001/XMLSchema#string